AbbVie, Galapagos Partner to Test Possible Chrohn's Disease Drug

AbbVie, North Chicago, Ill.-based pharmaceutical research and development company, is working with Galapagos, Mechelen, Belgium-based pharmaceutical company, to test if Janus kinase inhibitor can be used as a Chrohn's disease treatment, according to a Zenopa report.   

Galapagos will begin a phase II trial of the drug with 180 patients in 2014. The companies hope the drug will quickly move to a phase III trial.

More Articles on Gastroenterology:
8 Trends Shaping the Present & Future of Gastroenterology
Dr. Andrew Rhim Receives AGA Digestive Cancer Award, $40k Grant
Boston Scientific to Present Data at Digestive Disease Week



Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast